Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 10:25
12/01/22
12/01
10:25
12/01/22
10:25
ACET

Adicet Bio

$18.31 /

+0.12 (+0.66%)

, ACLX

Arcellx

$20.08 /

+0.12 (+0.60%)

, ALLO

Allogene Therapeutics

$9.46 /

-0.38 (-3.86%)

, BMY

Bristol-Myers

$80.52 /

+0.33 (+0.41%)

, CELU

Celularity

$1.78 /

+0.08 (+4.71%)

, CLLS

Cellectis

$2.22 /

+0.01 (+0.45%)

, CRBU

Caribou Biosciences

$9.18 /

-0.145 (-1.55%)

, CRSP

Crispr Therapeutics

$54.83 /

+0.04 (+0.07%)

, DTIL

Precision BioSciences

$1.37 /

+0.01 (+0.74%)

, FATE

Fate Therapeutics

$20.93 /

+0.1 (+0.48%)

, GILD

Gilead

$88.72 /

+0.87 (+0.99%)

, GRCL

Gracell

$3.32 /

+0.07 (+2.15%)

, IPSC

Century Therapeutics

$10.45 /

-0.02 (-0.19%)

, JNJ

Johnson & Johnson

$178.00 /

+0.03 (+0.02%)

, LEGN

Legend Biotech

$51.29 /

-0.035 (-0.07%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.43 /

-0.03 (-0.35%)

, PSTX

Poseida Therapeutics

$4.63 /

+0.09 (+1.98%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.78 /

+0.08 (+4.71%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$88.72 /

+0.87 (+0.99%)

12/01/22 Oppenheimer
Gilead price target raised to $105 from $95 at Oppenheimer
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
GRCL Gracell
$3.32 /

+0.07 (+2.15%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
ACET

Adicet Bio

$18.20 /

+0.42 (+2.36%)

, ACLX

Arcellx

$19.90 /

+ (+0.00%)

, ALLO

Allogene Therapeutics

$9.84 /

+0.56 (+6.03%)

, BMY

Bristol-Myers

$80.19 /

+1.18 (+1.49%)

, CELU

Celularity

$1.71 /

+0.035 (+2.10%)

, CLLS

Cellectis

$2.22 /

+0.04 (+1.83%)

, CRBU

Caribou Biosciences

$9.33 /

+0.985 (+11.81%)

, CRSP

Crispr Therapeutics

$54.69 /

+1.78 (+3.36%)

, DTIL

Precision BioSciences

$1.36 /

+0.06 (+4.62%)

, FATE

Fate Therapeutics

$20.84 /

+1.07 (+5.41%)

, GILD

Gilead

$87.85 /

+2.09 (+2.44%)

, GRCL

Gracell

$3.28 /

+0.04 (+1.23%)

, IPSC

Century Therapeutics

$10.48 /

+0.14 (+1.35%)

, JNJ

Johnson & Johnson

$177.94 /

+1.895 (+1.08%)

, LEGN

Legend Biotech

$51.25 /

+2.64 (+5.43%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.46 /

+0.365 (+4.51%)

, PSTX

Poseida Therapeutics

$4.54 /

+0.125 (+2.83%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$19.90 /

+ (+0.00%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.71 /

+0.035 (+2.10%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$87.85 /

+2.09 (+2.44%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
GRCL Gracell
$3.28 /

+0.04 (+1.23%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
11/28/22 Morgan Stanley
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

Over a week ago
Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 16:34
11/28/22
11/28
16:34
11/28/22
16:34
ACET

Adicet Bio

$16.71 /

-0.41 (-2.39%)

, ACLX

Arcellx

$20.13 /

-1.52 (-7.02%)

, ALLO

Allogene Therapeutics

$10.27 /

-0.515 (-4.78%)

, BMY

Bristol-Myers

$79.13 /

+ (+0.00%)

, CELU

Celularity

$1.63 /

+0.04 (+2.52%)

, CLLS

Cellectis

$2.24 /

-0.11 (-4.68%)

, CRBU

Caribou Biosciences

$8.53 /

-0.32 (-3.62%)

, CRSP

Crispr Therapeutics

$53.39 /

-1.54 (-2.80%)

, DTIL

Precision BioSciences

$1.35 /

-0.045 (-3.23%)

, FATE

Fate Therapeutics

$19.28 /

-0.54 (-2.72%)

, GILD

Gilead

$85.23 /

-1.04 (-1.21%)

, GRCL

Gracell

$3.13 /

-0.475 (-13.18%)

, IPSC

Century Therapeutics

$10.35 /

-0.15 (-1.43%)

, JNJ

Johnson & Johnson

$177.31 /

+0.11 (+0.06%)

, LEGN

Legend Biotech

$48.12 /

+0.09 (+0.19%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.09 /

-0.525 (-6.10%)

, PSTX

Poseida Therapeutics

$4.06 /

-0.34 (-7.73%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$79.13 /

+ (+0.00%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.63 /

+0.04 (+2.52%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$85.23 /

-1.04 (-1.21%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
GRCL Gracell
$3.13 /

-0.475 (-13.18%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
11/02/22 Morgan Stanley
Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/22 Deutsche Bank
Abiomed downgraded to Hold from Buy at Deutsche Bank
11/01/22 Piper Sandler
Abiomed downgraded to Neutral from Overweight at Piper Sandler
LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.06 /

-0.34 (-7.73%)

NKTX Nkarta
$8.09 /

-0.525 (-6.10%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

DTIL Precision BioSciences
$1.35 /

-0.045 (-3.23%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

CLLS Cellectis
$2.24 /

-0.11 (-4.68%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

LEGN Legend Biotech
$48.12 /

+0.09 (+0.19%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

GRCL Gracell
$3.13 /

-0.475 (-13.18%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

FATE Fate Therapeutics
$19.28 /

-0.54 (-2.72%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CRBU Caribou Biosciences
$8.53 /

-0.32 (-3.62%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ALLO Allogene Therapeutics
$10.27 /

-0.515 (-4.78%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

ACET Adicet Bio
$16.71 /

-0.41 (-2.39%)

JNJ Johnson & Johnson
$177.31 /

+0.11 (+0.06%)

IPSC Century Therapeutics
$10.35 /

-0.15 (-1.43%)

GILD Gilead
$85.23 /

-1.04 (-1.21%)

CRSP Crispr Therapeutics
$53.39 /

-1.54 (-2.80%)

CELU Celularity
$1.63 /

+0.04 (+2.52%)

BMY Bristol-Myers
$79.13 /

+ (+0.00%)

ACLX Arcellx
$20.13 /

-1.52 (-7.02%)

Hot Stocks
Tenaya Therapeutics receives orphan drug designation for TN-401 » 08:50
11/28/22
11/28
08:50
11/28/22
08:50
TNYA

Tenaya Therapeutics

$2.59 /

+0.15 (+6.15%)

Tenaya Therapeutics…

Tenaya Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation for its second gene therapy product candidate, TN-401, for the treatment of arrhythmogenic right ventricular cardiomyopathy. TN-401 is an adeno-associated virus-based gene therapy being developed for the treatment of genetic ARVC caused by Plakophilin-2 gene mutations. Mutations of the PKP2 gene can cause severe disease, including enlargement of the right ventricle in affected individuals, cardiac dysfunction, significant arrhythmia and sudden cardiac death in adults and children. PKP2 mutations are the most common genetic cause of ARVC, estimated to represent approximately 40 percent of the overall ARVC population and to effect more than 70,000 people in the U.S. alone. TN-401 is designed to use an AAV9 vector to deliver a healthy copy of the PKP2 gene to the heart muscle of affected patients via a single intravenous dose. Current treatments do not address the underlying genetic cause of disease and do not appear to affect disease progression. Tenaya intends to initiate a global non-interventional study of ARVC PKP2 gene mutation carriers by the end of this year in order to collect treatment history and data on seroprevalence to AAV antibodies. Tenaya expects to submit an Investigational New Drug application for the program to the FDA in 2023.

ShowHide Related Items >><<
TNYA Tenaya Therapeutics
$2.59 /

+0.15 (+6.15%)

TNYA Tenaya Therapeutics
$2.59 /

+0.15 (+6.15%)

11/11/22 Chardan
Tenaya Therapeutics price target lowered to $28 from $30 at Chardan
11/07/22 Canaccord
Tenaya Therapeutics initiated with a Buy at Canaccord
07/06/22 Piper Sandler
Tenaya journal publication validating for platform, says Piper Sandler
06/15/22 H.C. Wainwright
Tenaya Therapeutics initiated with a Buy at H.C. Wainwright
TNYA Tenaya Therapeutics
$2.59 /

+0.15 (+6.15%)

  • 17
    Nov
Hot Stocks
Tenaya treatment for ARVC due to PKP2 mutations granted orphan designation » 13:25
11/22/22
11/22
13:25
11/22/22
13:25
TNYA

Tenaya Therapeutics

$2.48 /

+0.14 (+5.98%)

Tenaya Therapeutics'…

Tenaya Therapeutics' treatment for arrhythmogenic right ventricular cardiomyopathy, or ARVC, due to PKP2 mutations was granted Orphan Designation by the FDA, according to a post to the agency's website. Reference Link

ShowHide Related Items >><<
TNYA Tenaya Therapeutics
$2.48 /

+0.14 (+5.98%)

TNYA Tenaya Therapeutics
$2.48 /

+0.14 (+5.98%)

11/11/22 Chardan
Tenaya Therapeutics price target lowered to $28 from $30 at Chardan
11/07/22 Canaccord
Tenaya Therapeutics initiated with a Buy at Canaccord
07/06/22 Piper Sandler
Tenaya journal publication validating for platform, says Piper Sandler
06/15/22 H.C. Wainwright
Tenaya Therapeutics initiated with a Buy at H.C. Wainwright
TNYA Tenaya Therapeutics
$2.48 /

+0.14 (+5.98%)

  • 17
    Nov
Syndicate
Tenaya Therapeutics 22.6M share Spot Secondary priced at $2.60 » 06:18
11/17/22
11/17
06:18
11/17/22
06:18
TNYA

Tenaya Therapeutics

$3.20 /

+0.31 (+10.73%)

Morgan Stanley and Piper…

Morgan Stanley and Piper Sandler acted as joint book running managers for the offering.

ShowHide Related Items >><<
TNYA Tenaya Therapeutics
$3.20 /

+0.31 (+10.73%)

TNYA Tenaya Therapeutics
$3.20 /

+0.31 (+10.73%)

11/11/22 Chardan
Tenaya Therapeutics price target lowered to $28 from $30 at Chardan
11/07/22 Canaccord
Tenaya Therapeutics initiated with a Buy at Canaccord
07/06/22 Piper Sandler
Tenaya journal publication validating for platform, says Piper Sandler
06/15/22 H.C. Wainwright
Tenaya Therapeutics initiated with a Buy at H.C. Wainwright
TNYA Tenaya Therapeutics
$3.20 /

+0.31 (+10.73%)

  • 17
    Nov
Syndicate
Tenaya Therapeutics announces $75M common stock offering » 16:04
11/16/22
11/16
16:04
11/16/22
16:04
TNYA

Tenaya Therapeutics

$3.20 /

+0.31 (+10.73%)

Tenaya Therapeutics…

Tenaya Therapeutics announced that it intends to offer and sell $75M of shares of common stock in an underwritten public offering. Morgan Stanley and Piper Sandler are acting as joint book-running managers for the proposed offering. H.C. Wainwright & Co. and Chardan are acting as co-lead managers for the proposed offering.

ShowHide Related Items >><<
TNYA Tenaya Therapeutics
$3.20 /

+0.31 (+10.73%)

TNYA Tenaya Therapeutics
$3.20 /

+0.31 (+10.73%)

11/11/22 Chardan
Tenaya Therapeutics price target lowered to $28 from $30 at Chardan
11/07/22 Canaccord
Tenaya Therapeutics initiated with a Buy at Canaccord
07/06/22 Piper Sandler
Tenaya journal publication validating for platform, says Piper Sandler
06/15/22 H.C. Wainwright
Tenaya Therapeutics initiated with a Buy at H.C. Wainwright
TNYA Tenaya Therapeutics
$3.20 /

+0.31 (+10.73%)

Recommendations
Poseida Therapeutics price target lowered to $14 from $20 at BTIG » 08:49
11/11/22
11/11
08:49
11/11/22
08:49
PSTX

Poseida Therapeutics

$4.53 /

+0.195 (+4.50%)

, RHHBY

Roche

$42.53 /

+1.17 (+2.83%)

, TAK

Takeda Pharmaceutical

$13.85 /

+0.635 (+4.81%)

BTIG analyst Justin Zelin…

BTIG analyst Justin Zelin lowered the firm's price target on Poseida Therapeutics (PSTX) to $14 from $20 as he updates his model after Q3 results and Auto PSMA discontinuation but keeps a Buy rating on the shares. The company's update highlighted its continued pipeline progress on wholly-owned assets and partnered programs with Roche (RHHBY) on CAR-T and Takeda (TAK) on gene therapy, the analyst tells investors in a research note. Zelin adds that he looks forward to early signals of efficacy in the multiple myeloma study given prior validation from autoCAR-T P-BCMA-101 with advantages expected in the allo product.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$13.85 /

+0.635 (+4.81%)

RHHBY Roche
$42.53 /

+1.17 (+2.83%)

PSTX Poseida Therapeutics
$4.53 /

+0.195 (+4.50%)

PSTX Poseida Therapeutics
$4.53 /

+0.195 (+4.50%)

08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
03/02/22
Poseida Therapeutics management to meet virtually with Piper Sandler
RHHBY Roche
$42.53 /

+1.17 (+2.83%)

10/25/22 Capital One
Arvinas initiated with an Overweight at Capital One
10/17/22 Morgan Stanley
Roche's AD drug expected to fall short in trial, says Morgan Stanley
10/12/22 Stifel
Biogen upgraded to Buy from Hold at Stifel
10/11/22 Morgan Stanley
Arcus Biosciences initiated with an Overweight at Morgan Stanley
TAK Takeda Pharmaceutical
$13.85 /

+0.635 (+4.81%)

10/05/22 H.C. Wainwright
H.C. Wainwright has more confidence in Astria opportunity after KalVista news
07/29/22 Jefferies
Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
07/19/22 Cowen
Takeda Pharmaceutical upgraded to Outperform from Market Perform at Cowen
RHHBY Roche
$42.53 /

+1.17 (+2.83%)

PSTX Poseida Therapeutics
$4.53 /

+0.195 (+4.50%)

  • 04
    Aug
TAK Takeda Pharmaceutical
$13.85 /

+0.635 (+4.81%)

RHHBY Roche
$42.53 /

+1.17 (+2.83%)

RHHBY Roche
$42.53 /

+1.17 (+2.83%)

Recommendations
Tenaya Therapeutics price target lowered to $28 from $30 at Chardan » 07:17
11/11/22
11/11
07:17
11/11/22
07:17
TNYA

Tenaya Therapeutics

$2.02 /

+0.12 (+6.32%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits lowered the firm's price target on Tenaya Therapeutics to $28 from $30 and keeps a Buy rating on the shares post the Q3 results.

ShowHide Related Items >><<
TNYA Tenaya Therapeutics
$2.02 /

+0.12 (+6.32%)

TNYA Tenaya Therapeutics
$2.02 /

+0.12 (+6.32%)

11/07/22 Canaccord
Tenaya Therapeutics initiated with a Buy at Canaccord
07/06/22 Piper Sandler
Tenaya journal publication validating for platform, says Piper Sandler
06/15/22 H.C. Wainwright
Tenaya Therapeutics initiated with a Buy at H.C. Wainwright
01/11/22 Piper Sandler
Piper Sandler says the Street missed Tenaya Therapeutics' new updates
TNYA Tenaya Therapeutics
$2.02 /

+0.12 (+6.32%)

Earnings
Tenaya Therapeutics reports Q3 EPS (74c), consensus (64c) » 17:02
11/10/22
11/10
17:02
11/10/22
17:02
TNYA

Tenaya Therapeutics

$2.02 /

+0.12 (+6.32%)

As of September 30, cash,…

As of September 30, cash, cash equivalents and investments in marketable securities were $149.5M. Through prioritization of certain R&D and manufacturing expenditures, plus management of future headcount growth, Tenaya expects existing funds to extend the company's cash runway to mid-2024. "The initiation of our first clinical trial for TN-301 during the third quarter was a major milestone marking our transition to a clinical-stage company. Our unwavering commitment to improve the lives of those affected by heart disease also requires careful management of finite resources and prioritization of portfolio opportunities," said Faraz Ali, CEO of Tenaya. "With the extension of our cash runway to mid-2024, we believe we can reach meaningful milestones for our more advanced product candidates, TN-201, TN-301 and TN-401, and still continue to selectively invest in research efforts to advance our deep pipeline of earlier-stage programs."

ShowHide Related Items >><<
TNYA Tenaya Therapeutics
$2.02 /

+0.12 (+6.32%)

TNYA Tenaya Therapeutics
$2.02 /

+0.12 (+6.32%)

11/07/22 Canaccord
Tenaya Therapeutics initiated with a Buy at Canaccord
07/06/22 Piper Sandler
Tenaya journal publication validating for platform, says Piper Sandler
06/15/22 H.C. Wainwright
Tenaya Therapeutics initiated with a Buy at H.C. Wainwright
01/11/22 Piper Sandler
Piper Sandler says the Street missed Tenaya Therapeutics' new updates
TNYA Tenaya Therapeutics
$2.02 /

+0.12 (+6.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.